Reference - Detail
| RRC ID | 38116 |
|---|---|
| Author | Kawano M, Tanaka K, Itonaga I, Iwasaki T, Miyazaki M, Ikeda S, Tsumura H. |
| Title | Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma. |
| Journal | Oncol Rep |
| Abstract |
We attempted to enhance the antitumor effects of tumor lysate-pulsed dendritic cells by eliminating regulatory T cells. The combinatorial effects of dendritic cells and agonist anti-glucocorticoid-induced tumor necrosis factor receptor (anti-GITR) antibodies were investigated with respect to enhancement of the systemic immune response, elimination of regulatory T cells, and inhibition of tumor growth. To determine whether the combination of dendritic cells and anti‑GITR antibodies could enhance systemic immune responses and inhibit primary tumor growth in a murine osteosarcoma (LM8) model. We established the following 4 groups of C3H mice (20 mice in total): i), control IgG-treated mice; ii), tumor lysate-pulsed dendritic cell‑treated mice; iii), agonist anti-GITR antibody-treated mice; and iv), agonist anti-GITR antibody- and tumor lysate-pulsed dendritic cell‑treated mice.The mice that received the agonist anti-GITR antibodies and tumor lysate-pulsed dendritic cells displayed inhibited primary growth, prolonged life time, reduced numbers of regulatory T lymphocytes in the spleen, elevated serum interferon-γ levels, increased number of CD8+ T lymphocytes. The mice that received combined therapy had reduced level of immunosuppressive cytokines in tumor tissue and serum. Combining agonist anti-GITR antibodies with tumor lysate-pulsed dendritic cells enhanced the systemic immune response. These findings provide further support for the continued development of agonist anti-GITR antibodies as an immunotherapeutic strategy for osteosarcoma. We suggest that our proposed immunotherapy could be developed further to improve osteosarcoma treatment. |
| Volume | 34(4) |
| Pages | 1995-2001 |
| Published | 2015-10-1 |
| DOI | 10.3892/or.2015.4161 |
| PMID | 26239052 |
| MeSH | Animals Antibodies, Anti-Idiotypic / administration & dosage* Antibodies, Anti-Idiotypic / immunology CD8-Positive T-Lymphocytes / immunology Cell Proliferation / genetics Cell- and Tissue-Based Therapy Dendritic Cells / immunology* Glucocorticoid-Induced TNFR-Related Protein / antagonists & inhibitors Glucocorticoid-Induced TNFR-Related Protein / immunology* Humans Immunity, Innate / immunology* Immunotherapy Mice Osteosarcoma / immunology* Osteosarcoma / pathology Osteosarcoma / therapy T-Lymphocytes, Regulatory / immunology |
| IF | 3.417 |
| Times Cited | 10 |
| WOS Category | ONCOLOGY |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | X(Twitter) |
| Total number of mentions | 2 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | LM8(RCB1450) |